Mirae Asset Global Investments Co. Ltd. Buys 18,357 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Mirae Asset Global Investments Co. Ltd. grew its stake in Exact Sciences Co. (NASDAQ:EXASGet Rating) by 19.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,740 shares of the medical research company’s stock after acquiring an additional 18,357 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Exact Sciences were worth $7,882,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. ARK Investment Management LLC increased its stake in shares of Exact Sciences by 6.1% during the first quarter. ARK Investment Management LLC now owns 14,323,962 shares of the medical research company’s stock valued at $1,001,531,000 after buying an additional 827,948 shares during the period. Capital World Investors increased its position in Exact Sciences by 17.2% during the 1st quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock valued at $383,652,000 after purchasing an additional 804,159 shares during the period. Farallon Capital Management LLC increased its position in Exact Sciences by 149.4% during the 1st quarter. Farallon Capital Management LLC now owns 802,898 shares of the medical research company’s stock valued at $56,139,000 after purchasing an additional 481,000 shares during the period. Spyglass Capital Management LLC raised its holdings in shares of Exact Sciences by 18.3% in the 4th quarter. Spyglass Capital Management LLC now owns 2,669,716 shares of the medical research company’s stock valued at $207,784,000 after purchasing an additional 413,713 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Exact Sciences by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 15,641,994 shares of the medical research company’s stock worth $1,093,688,000 after purchasing an additional 210,260 shares during the period. 90.95% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Katherine S. Zanotti sold 1,086 shares of the firm’s stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the transaction, the director now owns 60,318 shares in the company, valued at approximately $2,420,561.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of Exact Sciences stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the sale, the director now directly owns 60,318 shares in the company, valued at approximately $2,722,754.52. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Katherine S. Zanotti sold 1,086 shares of the stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total transaction of $43,581.18. Following the completion of the sale, the director now owns 60,318 shares in the company, valued at approximately $2,420,561.34. The disclosure for this sale can be found here. Insiders have sold 5,701 shares of company stock valued at $251,872 over the last ninety days. 1.30% of the stock is currently owned by insiders.

Exact Sciences Trading Down 4.2 %

Shares of Exact Sciences stock opened at $36.30 on Thursday. The firm’s 50 day simple moving average is $41.65 and its two-hundred day simple moving average is $50.65. The firm has a market capitalization of $6.42 billion, a price-to-earnings ratio of -8.58 and a beta of 1.37. Exact Sciences Co. has a 12-month low of $34.16 and a 12-month high of $106.27. The company has a current ratio of 2.48, a quick ratio of 2.23 and a debt-to-equity ratio of 0.70.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on EXAS. Citigroup cut their price objective on shares of Exact Sciences from $65.00 to $50.00 and set a “neutral” rating on the stock in a report on Wednesday, August 3rd. Craig Hallum reduced their price target on Exact Sciences from $81.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, August 3rd. Raymond James cut their target price on Exact Sciences from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 3rd. BTIG Research reduced their target price on shares of Exact Sciences from $100.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday, August 3rd. Finally, Piper Sandler lowered their price target on shares of Exact Sciences from $50.00 to $40.00 and set an “overweight” rating on the stock in a report on Wednesday, August 17th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $69.14.

Exact Sciences Company Profile

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Read More

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASGet Rating).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.